Literature DB >> 30776648

The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors.

Maria Diab1, Charles A Schiffer2.   

Abstract

Entities:  

Year:  2019        PMID： 30776648     DOI： 10.1016/j.leukres.2019.02.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  3 in total

Review 1.  Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice.

Authors:  Richard E Clark
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 2.  Treatment-Free Remission: the New Goal in CML Therapy.

Authors:  Ehab Atallah; Kendra Sweet
Journal:  Curr Hematol Malig Rep       Date:  2021-10-07       Impact factor: 3.952

Review 3.  Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success.

Authors:  Elena Inzoli; Andrea Aroldi; Rocco Piazza; Carlo Gambacorti-Passerini
Journal:  Am J Hematol       Date:  2022-04-12       Impact factor: 13.265
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.